By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioPorto Diagnostics A/S 

Grusbakken 8

  Gentofte  DK-2820  Denmark
Phone: 1-45-4529-0000 Fax: 1-45-4529-0001



Company News
BioPorto Release: Interim Report, Second Quarter Of 2017 8/10/2017 12:40:49 PM
BioPorto Release: Strong Data From Previous NGAL Study Provides The Basis For New Protocol And FDA Registration Application 7/14/2017 10:37:55 AM
BioPorto Release: NGAL Demonstrates Positive Economic Outcomes: Greatly Reduces Costs Associated With Diagnosis And Treatment Of Acute Kidney Injury 6/7/2017 10:14:20 AM
BioPorto Release: First Patient Recruited For The NGAL Test Clinical Study In The US. 4/12/2017 10:37:10 AM
Clinical Leaders Reinforce Belief In NGAL For Detection Of AKI Following FDA's Decision On BioPorto's The NGAL Test 6/6/2016 3:56:26 PM
BioPorto Maintains Its Assessment Of The IP Situation Regarding NGAL And Continue With The Divisional Application 6/30/2014 8:02:27 AM
Interim Financial Report For Q1 2014 For The BioPorto 5/6/2014 9:21:54 AM
BioPorto Release: Development Of Annual General Meeting 4/10/2014 7:52:43 AM
BioPorto Release: Announcement From Major Shareholder Regarding The AGM On April 9, 2014 4/9/2014 8:44:21 AM
EPO Rules BioPorto’s NGAL Cutoff-Patent Invalid 4/1/2014 9:44:11 AM